On the basis of hosting 6 national and provincial level research projects, Prof. Liang Liu recently received support from the National Natural Science Foundation of China again as the project leader to host another national research project (National Natural Science Foundation of China, 81472670) for nearly 1,000,000 RMB, with the research direction of “The effect of HBV infection on the malignant potential and poor clinical prognosis of pancreatic cancer The research is about the impact of HBV infection on the malignant potential and poor clinical prognosis of pancreatic cancer and its mechanism. This is another brand-new topic since Prof. Liu Liang received the same level of support in 2012 (National Natural Science Foundation of China, 81172005, “The regulation of Cavin on the temporal specificity of Caveolin-1 and the correlation with the malignant potential of pancreatic cancer”). Tumorigenesis and development originate from multiple factors. As far as biological factors are concerned, viruses and tumors are most closely related. For example, human papillomavirus (HPV), which is the most studied virus, is closely related to cervical cancer, and human hepatitis B virus (HBV), hepatitis C virus (HCV), herpes virus (EBV), immunodeficiency virus (HIV) and human T-cell leukemia virus (TLV) are all causative factors in the occurrence and development of human tumors. HBV infection directly induces the occurrence and development of primary liver cancer; specific attenuated or inactivated vaccination has become a basic national policy to prevent and treat liver cancer. It is worth noting that although the liver is the preferred target organ for HBV infection, there is still much evidence in recent years that HBV infection is also associated with the development of pancreatic cancer. After clinical practice and scientific research, Prof. Liu Liang’s team observed a large amount of HBV surface antigen (HBsAg) in the pancreatic fluid and pancreatic alveoli of HBV carriers; furthermore, genomic analysis of clinical pancreatic and pancreatic cancer specimens, including pancreatic cancer liver metastases, revealed that HBV-DNA integration and amplification existed in pancreatic cells regardless of benign or malignant; in particular, HBsAg was found in patients with “major triple-positive” disease. In particular, the amplification of HBV in the pancreatic parenchyma is more obvious in patients with “major triple-positive” disease, and the treatment effect is relatively poor. In order to explore this clinical phenomenon, the team plans to conduct a series of in vivo and ex vivo experimental studies in the next 5 years, aiming to systematically explain the unique biological characteristics and molecular mechanisms of HBV-infected pancreatic cancer patients in the field of basic scientific research, to find key targets for intervention, and to create a new clinical prospect for the application of anti-HBV therapy in pancreatic cancer in particular. This project is expected to be the only systematic clinical translational study in the international arena to investigate the correlation between HBV and the malignant potential of pancreatic cancer.